Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4607278 | 0.82 | CHRM2 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRNB2 | |
| SCHEMBL13191371 | 0.78 | CHRM2 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRNB2 | |
| SCHEMBL12304486 | 0.77 | CHRNA4 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRNB2 | |
| SCHEMBL29019856 | 0.75 | TSHR (0.40) | CHRM2CHRM4CHRM5CHRM1CHRNB2 | |
| SCHEMBL27797987 | 0.73 | — | — | |
| SCHEMBL3509561 | 0.71 | — | — | |
| SCHEMBL3512280 | 0.70 | — | — | |
| SCHEMBL14798711 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL20450562 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL8220484 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | NR0B2, NR0B1, NR4A3 | CHRM2 70/4885CHRM4 168/4885CHRM5 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.